Articles & Video
The Future of the Oligonucleotide and Peptide Therapeutics Industry
What changes could happen in the oligonucleotide and peptide therapeutics industry over the next decade? This interactive ebook gathers predictions from industry professionals all over the globe.
Emerging Therapies Content Library: Whitepapers and Reports Collection
Explore our collection of exclusive whitepapers and reports covering the most exciting developments in emerging therapies with one simple registration.
TIDES Europe Virtual 2020: Post-event Report
This report looks back at the top sessions and features of this year's TIDES Europe Virtual.
Peptide Therapies — Small Biomolecules Address Big Health Problems
This BioProcess International ebook looks at product research, manufacturing and regulatory concerns within the promising world of peptide therapies.
Oligonucleotides and peptides: the regulatory challenges
We investigate where current regulatory obstacles lie surrounding peptide and oligonucleotide therapeutics.
Strategies to Innovate the Production of Next Generation Bioconjugates
From developing ADCs to tumor-targeting, this whitepaper reviews the latest common challenges and novel strategies for producing bioconjugates.
Innovating CMC for Oligonucleotide and Peptide Therapeutics
In a new ebook, we look at ways to optimize chemistry manufacturing and controls for oligonucleotide and peptide therapeutics.
Partnering in the oligonucleotide and peptide therapeutics industry - WHITEPAPER
This whitepaper looks at the partnering challenges and opportunities facing the peptide and oligonucleotide therapeutics industry, using a number of case studies.
Manufacturing oligonucleotides: addressing safety and delivery challenges
We explore ways to tackle the main challenges in designing control strategies for oligonucleotide therapeutics.
Regulatory challenges and strategies for oligonucleotide, peptide and mRNA therapeutics - WHITEPAPER
We explore the regulatory challenges and successful approval strategies for oligonucleotide, peptide and mRNA therapeutics.
What is an oligonucleotide?
What is an oligonucleotide? Discover the different oligo classes and the future of oligonucleotide therapies.
Drug delivery trends in oligo, peptide, mRNA and CRISPR therapeutics
What are the current strategies and technology demands in delivering oligos, peptides mRNA and CRISPR therapeutics? We find out from our recent survey data.
How oligonucleotide, peptide, CRISPR and mRNA companies are using collaboration to move forward
We examined recent survey data to explore how collaboration is used by oligonucleotide, peptide, CRISPR and mRNA companies throughout their supply chains.
The future of peptide vaccines and personalized peptide therapies - WHITEPAPER
This whitepaper explores the exciting potential future of peptide vaccines and personalized peptide therapies.
REPORT: State of Oligo, Peptide, mRNA and CRISPR Therapeutics 2019
This exclusive report explores the state of the oligo, peptide, mRNA and CRISPR therapeutics industry in 2019 - download it here.
CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development - WHITEPAPER
This whitepaper explores the different CMC approaches to accelerate peptide, oligonucleotides and mRNA therapeutics development. Download it here.
Boosting commercialization of oligonucleotides as a raw materials supplier with Aldevron
Tom Lynch, Vice President of Sales & Client Development at Aldevron joined us at TIDES US in San Diego to discuss the company's role as a CDMO and how it is approaching the oligonucleotides market as a critical raw materials supplier.
ART BioScience’s mRNA-based treatment for Duchenne muscular dystrophy
Dr. Aleks Schein, Chief Scientific Officer at ART BioScience joined us to discuss its mRNA-based treatment for Duchenne muscular dystrophy and how the therapy could expand to other genetic disorders.
Collaborating to innovate: AstraZeneca's collaborations in mRNAs, antisense oligos and cell therapy
Anna Collén, Senior Project Director, Innovative Medicine at AstraZeneca, discusses how collaboration is driving innovation in mRNAs and antisense oligonucleotides at AZ.
Can GalNAc conjugated oligonucleotides still be improved?
GalNAc conjugated oligonucleotides: Marie Wikström Lindholm from Silence Therapeutics discusses how GalNAc conjugates can still be improved.
Drug Delivery of Oligonucleotides, Peptides, RNA, mRNA and CRISPR - WHITEPAPER
This whitepaper explores the latest innovations, strategies and challenges of drug delivery of oligonucleotides, peptides, RNA, mRNA and CRISPR. Download it here.
Oligo collaboration: The European Pharmaceutical Oligonucleotide Consortium
Oligo collaboration is essential for the development of new therapeutics. Rachel Orr from GSK, discusses the launch of the European Pharmaceutical Oligonucleotide Consortium (EPOC).